This week in drug discovery (26-30 May)
News round-up for 26-30 May by DDW Editor Reece Armstrong.
News stories of note for this week include a major deal signed between Eli Lilly and Rznomics in the field of RNA-editing therapies, and a potential quality-of-life breakthrough for patients with Parkinson’s.
Lilly and Rznomics agree $1.3 billion RNA-editing deal
Eli Lilly has entered into an agreement to develop and commercialise novel RNA-editing therapies using Rznomics’ proprietary trans-splicing ribozyme platform.
Breakthrough could boost quality of life for people with Parkinson’s disease
University of Queensland researchers have found that Gherlin, the natural ‘hunger hormone’, could be the key to preventing debilitating chronic constipation experienced by people living with Parkinson’s disease.
Weight loss start-up secures $7.8m investment
University of Michigan (U-M) spinout company Courage Therapeutics has received a seed investment of up to $7.8 million from Arsenal Bridge Ventures.
DDW’s Reece Armstrong looks at the latest announcements that came out of SLAS Europe.
Poolbeg granted FDA ODD for CRS cell therapy
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Poolbeg Pharma’s POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (CRS).